

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 December 2004 (16.12.2004)

PCT

(10) International Publication Number
WO 2004/108712 A1

(51) International Patent Classification⁷: **C07D 409/12**,
235/08, A61K 31/4184, A61P 29/00

D Montreal, 7171 Frederick-Banting, St Laurent, Québec
H4S 1Z9 (CA).

(21) International Application Number:
PCT/GB2004/002430

(74) Agent: **GLOBAL INTELLECTUAL PROPERTY**; As-
traZeneca AB, S-151 85 Södertälje (SE).

(22) International Filing Date: 9 June 2004 (09.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0301701-9 10 June 2003 (10.06.2003) SE

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(71) Applicant (for all designated States except MG, US): **AS-
TRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(71) Applicant (for MG only): **ASTRAZENECA UK LIM-
ITED** [GB/GB]; 15 Stanhope Gate, London Greater Lon-
don W1K 1LN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LIU, Zip-
ing** [CA/CA]; AstraZeneca R & D Montreal, 7171
Fredrick-Banting, St Laurent, Québec H4S 1Z9 (CA).
PAGÈ, Daniel [CA/CA]; AstraZeneca R & D Montreal,
7171 Fredrick-Banting, St Laurent, Québec H4S 1Z9 (CA).
WALPOLE, Christopher [GB/CA]; AstraZeneca R &
D Montreal, 7171 Frederick-Banting, St Laurent, Québec
H4S 1Z9 (CA). **YANG, Hua** [CA/CA]; AstraZeneca R &


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND
USES THEREOF



(57) Abstract: Compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4 and Z are as defined
in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in
therapy, in particular in the management of pain.



WO 2004/108712 A1

**BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM,
PREPARATION THEREOF AND USES THEREOF**

5 BACKGROUND OF THE INVENTION

1. Field of the invention

The invention is related to therapeutic compounds which are CB₁ receptor ligands, pharmaceutical compositions containing these compounds, manufacturing processes thereof and uses thereof, and more particularly to compounds that are CB₁ receptor agonists. More
10 particularly, the present invention is related to compounds that may be effective in treating pain, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and cardiovascular disorders.

2. Discussion of Relevant Technology

Pain management has been an important field of study for many years. It has been
15 well known that cannabinoid receptor (e.g., CB₁ receptor, CB₂ receptor) ligands including agonists, antagonists and inverse agonists produce relief of pain in a variety of animal models by interacting with CB₁ and/or CB₂ receptors. Generally, CB₁ receptors are located predominately in the central nervous system, whereas CB₂ receptors are located primarily in the periphery and are primarily restricted to the cells and tissues derived from the immune
20 system.

While CB₁ receptor agonists, such as Δ^9 -tetrahydrocannabinol (Δ^9 -THC) and anadamide, are useful in anti-nociception models in animals, they tend to exert undesired CNS side-effects, e.g., psychoactive side effects, the abuse potential, drug dependence and tolerance, etc. These undesired side effects are known to be mediated by the CB₁ receptors
25 located in CNS. There are lines of evidence, however, suggesting that CB₁ agonists acting at peripheral sites or with limited CNS exposure can manage pain in humans or animals with much improved overall in vivo profile.

Therefore, there is a need for new CB₁ receptor ligands such as agonists, antagonists or inverse agonists that are useful in managing pain or treating other related symptoms or
30 diseases with reduced or minimal undesirable CNS side-effects.

DISCLOSURE OF THE INVENTION

The present invention provides CB₁ receptor ligands which are useful in treating pain and other related symptoms or diseases.

Definitions

Unless specified otherwise within this specification, the nomenclature used in this specification generally follows the examples and rules stated in *Nomenclature of Organic Chemistry, Sections A, B, C, D, E, F, and H*, Pergamon Press, Oxford, 1979, which is
5 incorporated by references herein for its exemplary chemical structure names and rules on naming chemical structures. Optionally, a name of a compound may be generated using a chemical naming program: ACD/ChemSketch, Version 5.09/September 2001, Advanced Chemistry Development, Inc., Toronto, Canada.

"CB₁/CB₂ receptors" means CB₁ and/or CB₂ receptors.

10 The term "C_{m-n}" or "C_{m-n} group" used alone or as a prefix, refers to any group having m to n carbon atoms, and having 0 to n multivalent heteroatoms selected from O, S, N and P, wherein m and n are 0 or positive integers, and n>m. For example, "C₁₋₆" would refer to a chemical group having 1 to 6 carbon atoms, and having 0 to 6 multivalent heteroatoms selected from O, S, N and P.

15 The term "hydrocarbon" used alone or as a suffix or prefix, refers to any structure comprising only carbon and hydrogen atoms up to 14 carbon atoms.

The term "hydrocarbon radical" or "hydrocarbyl" used alone or as a suffix or prefix, refers to any structure as a result of removing one or more hydrogens from a hydrocarbon.

20 The term "alkyl" used alone or as a suffix or prefix, refers to monovalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms. Unless otherwise specified, "alkyl" general includes both saturated alkyl and unsaturated alkyl.

The term "alkylene" used alone or as suffix or prefix, refers to divalent straight or branched chain hydrocarbon radicals comprising 1 to about 12 carbon atoms, which serves to links two structures together.

25 The term "alkenyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 2 up to about 12 carbon atoms.

30 The term "alkynyl" used alone or as suffix or prefix, refers to a monovalent straight or branched chain hydrocarbon radical having at least one carbon-carbon triple bond and comprising at least 2 up to about 12 carbon atoms.

The term "cycloalkyl," used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical comprising at least 3 up to about 12 carbon atoms.

The term "cycloalkenyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon double bond and comprising at least 3 up to about 12 carbon atoms.

5 The term "cycloalkynyl" used alone or as suffix or prefix, refers to a monovalent ring-containing hydrocarbon radical having at least one carbon-carbon triple bond and comprising about 7 up to about 12 carbon atoms.

10 The term "aryl" used alone or as suffix or prefix, refers to a monovalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, wherein the radical is located on a carbon of the aromatic ring.

The term "non-aromatic group" or "non-aromatic" used alone, as suffix or as prefix, refers to a chemical group or radical that does not containing a ring having aromatic character (*e.g.*, $4n + 2$ delocalized electrons).

15 The term "arylene" used alone or as suffix or prefix, refers to a divalent hydrocarbon radical having one or more polyunsaturated carbon rings having aromatic character, (*e.g.*, $4n + 2$ delocalized electrons) and comprising 5 up to about 14 carbon atoms, which serves to links two structures together.

20 The term "heterocycle" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s). Heterocycle may be saturated or unsaturated, containing one or more double bonds, and heterocycle may contain more than one ring. When a heterocycle contains more than one ring, the rings may be fused or unfused. Fused rings generally refer to at least two rings share two atoms therebetween. Heterocycle may have aromatic character or may
25 not have aromatic character.

The term "heteroalkyl" used alone or as a suffix or prefix, refers to a radical formed as a result of replacing one or more carbon atom of an alkyl with one or more heteroatoms selected from N, O, P and S.

30 The term "heteroaromatic" used alone or as a suffix or prefix, refers to a ring-containing structure or molecule having one or more multivalent heteroatoms, independently selected from N, O, P and S, as a part of the ring structure and including at least 3 and up to about 20 atoms in the ring(s), wherein the ring-containing structure or molecule has an aromatic character (*e.g.*, $4n + 2$ delocalized electrons).

The term "heterocyclic group," "heterocyclic moiety," "heterocyclic," or "heterocyclo" used alone or as a suffix or prefix, refers to a radical derived from a heterocycle by removing one or more hydrogens therefrom.

5 The term "heterocyclyl" used alone or as a suffix or prefix, refers a monovalent radical derived from a heterocycle by removing one hydrogen from a carbon of a ring of the heterocycle.

The term "heterocyclylene" used alone or as a suffix or prefix, refers to a divalent radical derived from a heterocycle by removing two hydrogens therefrom, which serves to links two structures together.

10 The term "heteroaryl" used alone or as a suffix or prefix, refers to a heterocyclyl having aromatic character, wherein the radical of the heterocyclyl is located on a carbon of an aromatic ring of the heterocyclyl.

The term "heterocylcoalkyl" used alone or as a suffix or prefix, refers to a heterocyclyl that does not have aromatic character.

15 The term "heteroarylene" used alone or as a suffix or prefix, refers to a heterocyclylene having aromatic character.

The term "heterocycloalkylene" used alone or as a suffix or prefix, refers to a heterocyclylene that does not have aromatic character.

20 The term "six-membered" used as prefix refers to a group having a ring that contains six ring atoms.

The term "five-membered" used as prefix refers to a group having a ring that contains five ring atoms.

A five-membered ring heteroaryl is a heteroaryl with a ring having five ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

25 Exemplary five-membered ring heteroaryls are thienyl, furyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4- oxadiazolyl.

30 A six-membered ring heteroaryl is a heteroaryl with a ring having six ring atoms wherein 1, 2 or 3 ring atoms are independently selected from N, O and S.

Exemplary six-membered ring heteroaryls are pyridyl, pyrazinyl, pyrimidinyl, triazinyl and pyridazinyl.

- 5 -

The term "substituted" used as a prefix refers to a structure, molecule or group, wherein one or more hydrogens are replaced with one or more C₁₋₁₂hydrocarbon groups, or one or more chemical groups containing one or more heteroatoms selected from N, O, S, F, Cl, Br, I, and P. Exemplary chemical groups containing one or more heteroatoms include
5 heterocyclyl, -NO₂, -OR, -Cl, -Br, -I, -F, -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, -NRC(=O)R, oxo (=O), imino (=NR), thio (=S), and oximino (=N-OR), wherein each "R" is a C₁₋₁₂hydrocarbyl. For example, substituted phenyl may refer to nitrophenyl, pyridylphenyl, methoxyphenyl, chlorophenyl, aminophenyl, etc., wherein the nitro, pyridyl, methoxy, chloro, and amino
10 groups may replace any suitable hydrogen on the phenyl ring.

The term "substituted" used as a suffix of a first structure, molecule or group, followed by one or more names of chemical groups refers to a second structure, molecule or group, which is a result of replacing one or more hydrogens of the first structure, molecule or group with the one or more named chemical groups. For example, a "phenyl substituted by
15 nitro" refers to nitrophenyl.

The term "optionally substituted" refers to both groups, structures, or molecules that are substituted and those that are not substituted.

Heterocycle includes, for example, monocyclic heterocycles such as: aziridine, oxirane, thiirane, azetidine, oxetane, thietane, pyrrolidine, pyrroline, imidazolidine,
20 pyrazolidine, pyrazoline, dioxolane, sulfolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, thiophane, piperidine, 1,2,3,6-tetrahydro-pyridine, piperazine, morpholine, thiomorpholine, pyran, thiopyran, 2,3-dihydropyran, tetrahydropyran, 1,4-dihydropyridine, 1,4-dioxane, 1,3-dioxane, dioxane, homopiperidine, 2,3,4,7-tetrahydro-1*H*-azepine, homopiperazine, 1,3-dioxepane, 4,7-dihydro-1,3-dioxepin, and hexamethylene oxide.

25 In addition, heterocycle includes aromatic heterocycles, for example, pyridine, pyrazine, pyrimidine, pyridazine, thiophene, furan, furazan, pyrrole, imidazole, thiazole, oxazole, pyrazole, isothiazole, isoxazole, 1,2,3-triazole, tetrazole, 1,2,3-thiadiazole, 1,2,3-oxadiazole, 1,2,4-triazole, 1,2,4-thiadiazole, 1,2,4-oxadiazole, 1,3,4-triazole, 1,3,4-thiadiazole, and 1,3,4-oxadiazole.

30 Additionally, heterocycle encompass polycyclic heterocycles, for example, indole, indoline, isoindoline, quinoline, tetrahydroquinoline, isoquinoline, tetrahydroisoquinoline, 1,4-benzodioxan, coumarin, dihydrocoumarin, benzofuran, 2,3-dihydrobenzofuran, isobenzofuran, chromene, chroman, isochroman, xanthene, phenoxathiin, thianthrene,

indolizine, isoindole, indazole, purine, phthalazine, naphthyridine, quinoxaline, quinazoline, cinnoline, pteridine, phenanthridine, perimidine, phenanthroline, phenazine, phenothiazine, phenoxazine, 1,2-benzisoxazole, benzothiophene, benzoxazole, benzthiazole, benzimidazole, benztriazole, thioxanthine, carbazole, carboline, acridine, pyrolizidine, and quinolizidine.

5 In addition to the polycyclic heterocycles described above, heterocycle includes polycyclic heterocycles wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings. Examples of such bridged heterocycles include quinuclidine, diazabicyclo[2.2.1]heptane and 7-oxabicyclo[2.2.1]heptane.

10 Heterocyclyl includes, for example, monocyclic heterocyclyls, such as: aziridinyl, oxiranyl, thiranyl, azetidiny, oxetanyl, thietanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, pyrazolidinyl, pyrazolinyl, dioxolanyl, sulfolanyl, 2,3-dihydrofuranyl, 2,5-dihydrofuranyl, tetrahydrofuranyl, thiophanyl, piperidinyl, 1,2,3,6-tetrahydro-pyridinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyranyl, thiopyranyl, 2,3-dihydropyranyl, tetrahydropyranyl, 15 1,4-dihydropyridinyl, 1,4-dioxanyl, 1,3-dioxanyl, dioxanyl, homopiperidinyl, 2,3,4,7-tetrahydro-1*H*-azepinyl, homopiperazinyl, 1,3-dioxepanyl, 4,7-dihydro-1,3-dioxepinyl, and hexamethylene oxidyl.

In addition, heterocyclyl includes aromatic heterocyclyls or heteroaryl, for example, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, thienyl, furyl, furazanyl, pyrrolyl, imidazolyl, 20 thiazolyl, oxazolyl, pyrazolyl, isothiazolyl, isoxazolyl, 1,2,3-triazolyl, tetrazolyl, 1,2,3-thiadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-triazolyl, 1,2,4-thiadiazolyl, 1,2,4-oxadiazolyl, 1,3,4-triazolyl, 1,3,4-thiadiazolyl, and 1,3,4 oxadiazolyl.

Additionally, heterocyclyl encompasses polycyclic heterocyclyls (including both aromatic or non-aromatic), for example, indolyl, indolinyl, isoindolinyl, quinolinyl, 25 tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, 1,4-benzodioxanyl, coumarinyl, dihydrocoumarinyl, benzofuranyl, 2,3-dihydrobenzofuranyl, isobenzofuranyl, chromenyl, chromanyl, isochromanyl, xanthenyl, phenoxathiinyl, thianthrenyl, indolizinyl, isoindolyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, pteridinyl, phenanthridinyl, perimidinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, 30 phenoxazinyl, 1,2-benzisoxazolyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benzimidazolyl, benztriazolyl, thioxanthinyl, carbazolyl, carbolinyl, acridinyl, pyrolizidinyl, and quinolizidinyl.

- 7 -

In addition to the polycyclic heterocyclyls described above, heterocyclyl includes polycyclic heterocyclyls wherein the ring fusion between two or more rings includes more than one bond common to both rings and more than two atoms common to both rings.

Examples of such bridged heterocycles include quinuclidinyl, diazabicyclo[2.2.1]heptyl; and
5 7-oxabicyclo[2.2.1]heptyl.

The term "alkoxy" used alone or as a suffix or prefix, refers to radicals of the general formula -O-R, wherein -R is selected from a hydrocarbon radical. Exemplary alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, isobutoxy, cyclopropylmethoxy, allyloxy, and propargyloxy.

10 The term "aryloxy" used alone or as suffix or prefix, refers to radicals of the general formula -O-Ar, wherein -Ar is an aryl.

The term "heteroaryloxy" used alone or as suffix or prefix, refers to radicals of the general formula -O-Ar', wherein -Ar' is a heteroaryl.

The term "amine" or "amino" used alone or as a suffix or prefix, refers to radicals of
15 the general formula -NRR', wherein R and R' are independently selected from hydrogen or a hydrocarbon radical.

"Acyl" used alone, as a prefix or suffix, means -C(=O)-R, wherein -R is an optionally substituted hydrocarbyl, hydrogen, amino or alkoxy. Acyl groups include, for example, acetyl, propionyl, benzoyl, phenyl acetyl, carboethoxy, and dimethylcarbamoyl.

20 Halogen includes fluorine, chlorine, bromine and iodine.

"Halogenated," used as a prefix of a group, means one or more hydrogens on the group is replaced with one or more halogens.

"RT" or "rt" means room temperature.

A first ring group being "fused" with a second ring group means the first ring and the
25 second ring share at least two atoms therebetween.

"Link," "linked," or "linking," unless otherwise specified, means covalently linked or bonded.

When a first group, structure, or atom is "directly connected" to a second group, structure or atom, at least one atom of the first group, structure or atom forms a chemical bond
30 with at least one atom of the second group, structure or atom.

"Saturated carbon" means a carbon atom in a structure, molecule or group wherein all the bonds connected to this carbon atom are single bond. In other words, there is no double or

- 8 -


triple bonds connected to this carbon atom and this carbon atom generally adopts an sp^3 atomic orbital hybridization.

"Unsaturated carbon" means a carbon atom in a structure, molecule or group wherein at least one bond connected to this carbon atom is not a single bond. In other words, there is
 5 at least one double or triple bond connected to this carbon atom and this carbon atom generally adopts a sp or sp^2 atomic orbital hybridization.

In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The term "therapeutic" and "therapeutically" should be construed accordingly. The term "therapy" within the context of
 10 the present invention further encompasses to administer an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or a recurring condition. This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.

Summary of the Invention

15 This invention encompasses compounds in accord with formula I:



I

wherein

20 Z is selected from O= and S=;

R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R⁵R⁶N-C₁₋₆alkyl, R⁵O-C₁₋₆alkyl, R⁵C(=O)N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂-C₁₋₆alkyl, R⁵CS(=O)₂N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NC(=O)N(-R⁷)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂N(R⁷)-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, R⁵R⁶N-, R⁵O-, R⁵C(=O)N(-R⁶)-, R⁵R⁶NS(=O)₂-, R⁵CS(=O)₂N(-R⁶)-, R⁵R⁶NC(=O)N(-R⁷)-, R⁵R⁶NS(=O)₂N(R⁷)-, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl,
 25 C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino,
 30 C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino,

- 9 -

C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl or C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;

R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R⁵R⁶N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;

wherein R⁵, R⁶ and R⁷ are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, and a divalent C₁₋₆group that together with another divalent R⁵, R⁶ or R⁷ forms a portion of a ring; and

R³ is selected from R⁸, R⁸O-, and R⁸R⁹N-;


each of R⁴, R⁸ and R⁹ is independently selected from -H, C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₃₋₆heterocyclyl, C₆₋₁₀aryl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, and a divalent C₁₋₆group that together with another divalent group selected from R⁴, R⁸ and R⁹ forms a portion of a ring, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₃₋₆heterocyclyl, C₆₋₁₀aryl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, or divalent C₁₋₆group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶.

The invention also encompasses stereoisomers, enantiomers, diastereomers, racemates or mixtures thereof, *in-vivo*-hydrolysable precursors and pharmaceutically-acceptable salts of compounds of formula I, solvated or unsolvated forms of compounds of formula I, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them, uses of them as medicaments, uses of them in the manufacture of medicaments and uses of them for diagnostic and analytic purposes.

Description of Preferred Embodiments

- 10 -

In one aspect, the invention provides a compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:

**I**

5 wherein

Z is selected from O= and S=;

R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R⁵R⁶N-C₁₋₆alkyl, R⁵O-C₁₋₆alkyl, R⁵C(=O)N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂-C₁₋₆alkyl, R⁵CS(=O)₂N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NC(=O)N(-R⁷)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂N(R⁷)-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, R⁵R⁶N-, R⁵O-, R⁵C(=O)N(-R⁶)-, R⁵R⁶NS(=O)₂-, R⁵CS(=O)₂N(-R⁶)-, R⁵R⁶NC(=O)N(-R⁷)-, R⁵R⁶NS(=O)₂N(R⁷)-, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl or C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;

R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R⁵R⁶N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;

wherein R⁵, R⁶ and R⁷ are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, and a divalent C₁₋₆group that together with another divalent R⁵, R⁶ or R⁷ forms a portion of a ring; and

R^3 is selected from R^8 , R^8O- , and R^8R^9N- ;

each of R^4 , R^8 and R^9 is independently selected from $-H$, $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-10}cycloalkyl$, $C_{3-10}cycloalkyl-C_{1-6}alkyl$, $C_{3-6}heterocyclyl$, $C_{6-10}aryl$, $C_{3-6}heterocyclyl-C_{1-6}alkyl$, $C_{6-10}aryl-C_{1-6}alkyl$, and a divalent C_{1-6} group that together with another divalent group selected from R^4 , R^8 and R^9 forms a portion of a ring, wherein said $C_{1-10}alkyl$, $C_{2-10}alkenyl$, $C_{2-10}alkynyl$, $C_{3-10}cycloalkyl$, $C_{3-10}cycloalkyl-C_{1-6}alkyl$, $C_{3-6}heterocyclyl$, $C_{6-10}aryl$, $C_{3-6}heterocyclyl-C_{1-6}alkyl$, $C_{6-10}aryl-C_{1-6}alkyl$, or divalent C_{1-6} group is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$.

Particularly, the compounds of the present invention are those of formula I, wherein Z is $O=$;

R^1 is selected from $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, $R^5R^6N-C_{1-4}alkyl$, $R^5O-C_{1-4}alkyl$, $R^5C(=O)N(-R^6)-C_{1-4}alkyl$, phenyl- $C_{1-4}alkyl$, phenyl- $C(=O)-C_{1-4}alkyl$, $C_{3-10}cycloalkyl-C_{1-4}alkyl$, $C_{4-6}cycloalkenyl-C_{1-4}alkyl$, $C_{3-6}heterocyclyl-C_{1-4}alkyl$, $C_{3-6}heterocyclyl-C(=O)-C_{1-4}alkyl$, R^5R^6N- , R^5O- , $R^5R^6NS(=O)_2-$, $C_{6-10}aryl$, $C_{6-10}aryl-C(=O)-$, $C_{3-10}cycloalkyl$, $C_{4-6}cycloalkenyl$, $C_{3-6}heterocyclyl$ and $C_{3-6}heterocyclyl-C(=O)-$; wherein said $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{2-6}alkynyl$, phenyl- $C_{1-4}alkyl$, phenyl- $C(=O)-C_{1-4}alkyl$, $C_{3-10}cycloalkyl-C_{1-4}alkyl$, $C_{4-6}cycloalkenyl-C_{1-4}alkyl$, $C_{3-6}heterocyclyl-C_{1-4}alkyl$, $C_{3-6}heterocyclyl-C(=O)-C_{1-4}alkyl$, $C_{6-10}aryl$, $C_{6-10}aryl-C(=O)-$, $C_{3-10}cycloalkyl$, $C_{4-6}cycloalkenyl$, $C_{3-6}heterocyclyl$ or $C_{3-6}heterocyclyl-C(=O)-$ used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;

wherein R^5 and R^6 are independently selected from $-H$, $C_{1-6}alkyl$ and $C_{2-6}alkenyl$;

R^2 is selected from the group consisting of $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{3-6}cycloalkyl$, $C_{3-6}cycloalkyl-C_{1-4}alkyl$, $C_{4-6}cycloalkenyl-C_{1-4}alkyl$, $C_{3-6}heterocycloalkyl-C_{1-4}alkyl$, $C_{4-6}cycloalkenyl$, $C_{3-5}heteroaryl$, R^5R^6N- , phenyl and $C_{3-6}heterocycloalkyl$, wherein said $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{3-6}cycloalkyl$, $C_{3-6}cycloalkyl-C_{1-4}alkyl$, $C_{4-6}cycloalkenyl-C_{1-4}alkyl$, $C_{3-6}heterocycloalkyl-C_{1-4}alkyl$, $C_{4-6}cycloalkenyl$, $C_{3-5}heteroaryl$, phenyl or $C_{3-6}heterocycloalkyl$ used in defining R^2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; and

R^3 is selected from R^8 , R^8O- , R^8HN- and R^8R^9N- ;

R^8 and R^9 are independently selected from $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-4}alkyl$, $C_{3-6}heterocyclyl$, phenyl, $C_{3-6}heterocyclyl-C_{1-4}alkyl$, and phenyl- $C_{1-4}alkyl$, wherein said $C_{1-6}alkyl$, $C_{2-6}alkenyl$, $C_{3-8}cycloalkyl$, $C_{3-8}cycloalkyl-C_{1-4}alkyl$, $C_{3-6}heterocyclyl$

- 12 -

heterocyclyl, phenyl, C₃₋₆heterocyclyl-C₁₋₄alkyl, or phenyl-C₁₋₄alkyl is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; and

R⁴ is selected from -H, C₁₋₆alkyl and C₂₋₆alkenyl.

5 More particularly, the compounds of the present invention are those of formula I, wherein Z is O=;

R¹ is selected from C₁₋₆alkyl, C₂₋₆alkenyl, R⁵R⁶N-C₁₋₄alkyl, R⁵O-C₁₋₄alkyl, R⁵C(=O)N(-R⁶)-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, phenyl-C(=O)-C₁₋₄alkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₆alkyl, C₂₋₆alkenyl, R⁵R⁶N-C₁₋₄alkyl, R⁵O-C₁₋₄alkyl, R⁵C(=O)N(-R⁶)-C₁₋₄alkyl, phenyl-C₁₋₄alkyl, phenyl-C(=O)-C₁₋₄alkyl, C₃₋₁₀cycloalkyl-C₁₋₄alkyl, C₄₋₆cycloalkenyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C₁₋₄alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₄alkyl, phenyl, C₃₋₁₀cycloalkyl, C₃₋₆heterocyclyl or C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;

R² is selected from the group consisting of C₁₋₆alkyl, C₃₋₆cycloalkyl, R⁵R⁶N-, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₅heteroaryl, and phenyl wherein said C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl-C₁₋₄alkyl, C₃₋₆heterocycloalkyl, C₃₋₅heteroaryl, and phenyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;

R⁵ and R⁶ are independently selected from -H, C₁₋₆alkyl and C₂₋₆alkenyl; and

R³ is selected from R⁸, R⁸O-, R⁸HN- and R⁸R⁹N-;

25 R⁸ and R⁹ are independently selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₃₋₅heterocyclyl, phenyl, C₃₋₅heterocyclyl-C₁₋₄alkyl, and phenyl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkyl-C₁₋₄alkyl, C₃₋₅heterocyclyl, phenyl, C₃₋₅heterocyclyl-C₁₋₄alkyl, or phenyl-C₁₋₄alkyl is optionally substituted by one or more groups selected from halogen, cyano, methoxy, methyl, and ethyl; and

30 R⁴ is selected from -H and C₁₋₄alkyl.

Most particularly, the compounds of the present invention are those of formula I, wherein

Z is O=;

- 13 -

R¹ is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl, propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl, methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl, cyclohexyloxy, cyclohexylamino, dimethylaminoethyl, 4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl, 1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl, 2-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl, N-methyl-2-piperidylmethyl, 3-thienylmethyl, (2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl, (5-(acetoxymethyl)-2-furyl)methyl), (2,3-dihydro-1H-isoindole-1-yl)methyl, and 5-(2-methylthiazolyl);

R² is selected from t-butyl, n-butyl, 2-methyl-2-butyl, cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl, 1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl, tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and N-morpholinyl;

R³ is selected from methyl, ethyl, isopropyl, n-butyl, t-butyl, iso-butyl, phenyl, pyridyl, imidazolyl, naphthalenyl, isopropylamino and 2-thienyl; and

R⁴ is selected from -H, methyl and ethyl.

It will be understood that when compounds of the present invention contain one or more chiral centers, the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture. The present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of Formula I. The optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.

It will also be appreciated that certain compounds of the present invention may exist as geometrical isomers, for example E and Z isomers of alkenes. The present invention includes any geometrical isomer of a compound of Formula I. It will further be understood that the present invention encompasses tautomers of the compounds of the formula I.

It will also be understood that certain compounds of the present invention may exist in solvated, for example hydrated, as well as unsolvated forms. It will further be understood that the present invention encompasses all such solvated forms of the compounds of the formula I.

Within the scope of the invention are also salts of the compounds of the formula I. Generally, pharmaceutically acceptable salts of compounds of the present invention may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example,

- 14 -

HCl or acetic acid, to afford a physiologically acceptable anion. It may also be possible to make a corresponding alkali metal (such as sodium, potassium, or lithium) or an alkaline earth metal (such as a calcium) salt by treating a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali
5 metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.

In one embodiment, the compound of formula I above may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a
10 hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or *p*-toluenesulphonate.

We have now found that the compounds of the invention have activity as pharmaceuticals, in particular as modulators or ligands such as agonists, partial agonists, inverse agonist or antagonists of CB1 receptors. More particularly, the compounds of the
15 invention exhibit selective activity as agonist of the CB1 receptors and are useful in therapy, especially for relief of various pain conditions such as chronic pain, neuropathic pain, acute pain, cancer pain, pain caused by rheumatoid arthritis, migraine, visceral pain etc. This list should however not be interpreted as exhaustive. Additionally, compounds of the present invention are useful in other disease states in which dysfunction of CB1 receptors is present or
20 implicated. Furthermore, the compounds of the invention may be used to treat cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, anxiety disorders, gastrointestinal disorders and cardiovascular disorders.

Compounds of the invention are useful as immunomodulators, especially for autoimmune diseases, such as arthritis, for skin grafts, organ transplants and similar surgical
25 needs, for collagen diseases, various allergies, for use as anti-tumour agents and anti viral agents.

Compounds of the invention are useful in disease states where degeneration or dysfunction of cannabinoid receptors is present or implicated in that paradigm. This may involve the use of isotopically labelled versions of the compounds of the invention in
30 diagnostic techniques and imaging applications such as positron emission tomography (PET).

Compounds of the invention are useful for the treatment of diarrhoea, depression, anxiety and stress-related disorders such as post-traumatic stress disorders, panic disorder, generalized anxiety disorder, social phobia, and obsessive compulsive disorder, urinary

- 15 -

incontinence, premature ejaculation, various mental illnesses, cough, lung oedema, various gastro-intestinal disorders, e.g. constipation, functional gastrointestinal disorders such as Irritable Bowel Syndrome and Functional Dyspepsia, Parkinson's disease and other motor disorders, traumatic brain injury, stroke, cardioprotection following myocardial infarction, spinal injury and drug addiction, including the treatment of alcohol, nicotine, opioid and other drug abuse and for disorders of the sympathetic nervous system for example hypertension.

Compounds of the invention are useful as an analgesic agent for use during general anaesthesia and monitored anaesthesia care. Combinations of agents with different properties are often used to achieve a balance of effects needed to maintain the anaesthetic state (e.g. amnesia, analgesia, muscle relaxation and sedation). Included in this combination are inhaled anaesthetics, hypnotics, anxiolytics, neuromuscular blockers and opioids.

Also within the scope of the invention is the use of any of the compounds according to the formula I above, for the manufacture of a medicament for the treatment of any of the conditions discussed above.

A further aspect of the invention is a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to the formula I above, is administered to a patient in need of such treatment.

Thus, the invention provides a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.

In a further aspect, the present invention provides the use of a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined in the manufacture of a medicament for use in therapy.

The compounds of the present invention are useful in therapy, especially for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

In use for therapy in a warm-blooded animal such as a human, the compound of the invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracically, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.

In one embodiment of the invention, the route of administration may be orally, intravenously or intramuscularly.

- 16 -

The dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, when determining the individual regimen and dosage level at the most appropriate for a particular patient.

5 For preparing pharmaceutical compositions from the compounds of this invention, inert, pharmaceutically acceptable carriers can be either solid and liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets, and suppositories.

10 A solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and
15 compacted in the shape and size desired.

For preparing suppository compositions, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized moulds and allowed to cool and solidify.

20 Suitable carriers are magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter, and the like.

The term composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active
25 component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.

Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid form compositions include solutions, suspensions, and emulsions. For
30 example, sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration. Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.

- 17 -

Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired. Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural
5 synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.

Depending on the mode of administration, the pharmaceutical composition will preferably include from 0.05% to 99%w (per cent by weight), more preferably from 0.10 to 50%w, of the compound of the invention, all percentages by weight being based on total
10 composition.

A therapeutically effective amount for the practice of the present invention may be determined, by the use of known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented, by one of ordinary skills in the art.

15 Within the scope of the invention is the use of any compound of formula I as defined above for the manufacture of a medicament.

Also within the scope of the invention is the use of any compound of formula I for the manufacture of a medicament for the therapy of pain.

Additionally provided is the use of any compound according to Formula I for the
20 manufacture of a medicament for the therapy of various pain conditions including, but not limited to: acute pain, chronic pain, neuropathic pain, back pain, cancer pain, and visceral pain.

A further aspect of the invention is a method for therapy of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according
25 to the formula I above, is administered to a patient in need of such therapy.

Additionally, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.


Particularly, there is provided a pharmaceutical composition comprising a compound
30 of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier for therapy, more particularly for therapy of pain.

- 18 -


Further, there is provided a pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier use in any of the conditions discussed above.

In a further aspect, the present invention provides a method of preparing the compounds of the present invention.

In one embodiment, the invention provides a process for preparing a compound of formula II,

II

comprising the step of reacting a compound of formula III,

III

with a compound of $R^3C(=O)X$ to form the compound of formula II, wherein

X is selected from -Cl, -Br, -I, -OH, -OCH₃ and -OCH₂CH₃;

R^1 is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R⁵R⁶N-C₁₋₆alkyl, R⁵O-C₁₋₆alkyl, R⁵C(=O)N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂-C₁₋₆alkyl, R⁵CS(=O)₂N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NC(=O)N(-R⁷)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂N(R⁷)-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, R⁵R⁶N-, R⁵O-, R⁵C(=O)N(-R⁶)-, R⁵R⁶NS(=O)₂-, R⁵CS(=O)₂N(-R⁶)-, R⁵R⁶NC(=O)N(-R⁷)-, R⁵R⁶NS(=O)₂N(R⁷)-, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl or

C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;

R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R⁵R⁶N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;

wherein R⁵, R⁶ and R⁷ are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, and a divalent C₁₋₆group that together with another divalent R⁵, R⁶ or R⁷ forms a portion of a ring;

R³ is selected from R⁸, R⁸O-, R⁸NH-, and R⁸R⁹N-;

R⁸ and R⁹ are independently selected from C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₄alkyl, C₃₋₆heterocyclyl, phenyl, C₃₋₆heterocyclyl-C₁₋₄alkyl, and phenyl-C₁₋₄alkyl, wherein said C₁₋₆alkyl, C₂₋₆alkenyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₄alkyl, C₃₋₆heterocyclyl, phenyl, C₃₋₆heterocyclyl-C₁₋₄alkyl, or phenyl-C₁₋₄alkyl is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; and

R⁴ is selected from -H, C₁₋₆alkyl and C₂₋₆alkenyl.

Particularly, the present invention provides a method of preparing a compound of formula II, wherein Z is O=;

R¹ is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl, propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl, methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl, cyclohexyloxy, cyclohexylamino, dimethylaminoethyl, 4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl, 1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl, 2-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl, N-methyl-2-piperidylmethyl, 3-thienylmethyl, (2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl, (5-(acetoxymethyl)-2-furyl)methyl, (2,3-dihydro-1H-isoindole-1-yl)methyl, and 5-(2-methylthiazolyl);


- 20 -

R^2 is selected from t-butyl, n-butyl, 2-methyl-2-butyl, cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl, 1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl, tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and N-morpholinyl;


R^3 is selected from methyl, ethyl, isopropyl, n-butyl, t-butyl, iso-butyl, phenyl, pyridyl, imidazolyl, naphthalenyl, isopropylamino and 2-thienyl; and

R^4 is selected from -H, methyl and ethyl.

In a further aspect, the present invention provides a method for preparing a compound of formula IV,

**IV**

comprising the step of reacting a compound of formula V,

**V**

with a reducing agent selected from AlH_3 , $NaBH_4$, $NaBH(O-iPr)_3$, and $LiAlH_4$, wherein

R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, $R^5R^6N-C_{1-6}$ alkyl, R^5O-C_{1-6} alkyl, $R^5C(=O)N(-R^6)-C_{1-6}$ alkyl, $R^5R^6NS(=O)_2-C_{1-6}$ alkyl, $R^5CS(=O)_2N(-R^6)-C_{1-6}$ alkyl, $R^5R^6NC(=O)N(-R^7)-C_{1-6}$ alkyl, $R^5R^6NS(=O)_2N(R^7)-C_{1-6}$ alkyl, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)-C_{1-6}$ alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)-C_{1-6}$ alkyl, C_{1-10} hydrocarbylamino, R^5R^6N- , R^5O- , $R^5C(=O)N(-R^6)-$, $R^5R^6NS(=O)_2-$, $R^5CS(=O)_2N(-R^6)-$, $R^5R^6NC(=O)N(-R^7)-$, $R^5R^6NS(=O)_2N(R^7)-$, C_{6-10} aryl, C_{6-10} aryl- $C(=O)-$, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl- $C(=O)-$; wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)-C_{1-6}$ alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)-C_{1-6}$ alkyl, C_{1-10} hydrocarbylamino, C_{6-10} aryl, C_{6-10} aryl- $C(=O)-$, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl or

- 21 -

C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;

R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R⁵R⁶N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and – NR⁵R⁶;

wherein R⁵, R⁶ and R⁷ are independently selected from –H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, and a divalent C₁₋₆group that together with another divalent R⁵, R⁶ or R⁷ forms a portion of a ring; and

R¹⁰ is selected from –H, C₁₋₆alkyl, and C₁₋₆alkenyl.



Particularly, the present invention provides a method of preparing a compound of formula IV, wherein

R¹ is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl, propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl, methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl, cyclohexyloxy, cyclohexylamino, dimethylaminoethyl, 4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl, 1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl, 2-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl, N-methyl-2-piperidylmethyl, 3-thienylmethyl, (2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl, (5-(acetoxymethyl)-2-furyl)methyl, (2,3-dihydro-1H-isoindole-1-yl)methyl, and 5-(2-methylthiazolyl);

R² is selected from t-butyl, n-butyl, 2-methyl-2-butyl, cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl, 1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl, tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and N-morpholinyl; and

R¹⁰ is selected from –H and C₁₋₆alkyl.

Compounds of the present invention may be prepared according to the synthetic routes as depicted in Schemes 1 and 2 using one or more methods disclosed above.

Scheme 1. (A synthetic route used for the synthesis of compounds including Examples 1 to 6 and 8 to 11)**Scheme 2. (A synthetic route used for the synthesis of compounds including Examples 7 and 8)**

Biological Evaluation

hCB₁ and hCB₂ receptor binding

- 5 Human CB₁ receptor from Receptor Biology (hCB1) or human CB₂ receptor from BioSignal (hCB2) membranes are thawed at 37°C , passed 3 times through a 25-gauge blunt-end needle, diluted in the cannabinoid binding buffer (50 mM Tris, 2.5 mM EDTA, 5 mM MgCl_2 , and 0.5 mg/mL BSA fatty acid free, pH 7.4) and aliquots containing the appropriate amount of protein are distributed in 96-well plates. The IC_{50} of the compounds of the
- 10 invention at hCB₁ and hCB₂ are evaluated from 10-point dose-response curves done with ^3H -CP55,940 at 20000 to 25000 dpm per well (0.17-0.21 nM) in a final volume of 300 μl . The

- 23 -

total and non-specific binding are determined in the absence and presence of 0.2 μM of HU210 respectively. The plates are vortexed and incubated for 60 minutes at room temperature, filtered through Unifilters GF/B (presoaked in 0.1% polyethyleneimine) with the Tomtec or Packard harvester using 3 mL of wash buffer (50 mM Tris, 5 mM MgCl_2 , 0.5 mg BSA pH 7.0). The filters are dried for 1 hour at 55 $^{\circ}\text{C}$. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl /well of MS-20 scintillation liquid.

hCB₁ and hCB₂ GTP γ S binding

Human CB₁ receptor from Receptor Biology (hCB₁) or human CB₂ receptor membranes (BioSignal) are thawed at 37 $^{\circ}\text{C}$, passed 3 times through a 25-gauge blunt-end needle and diluted in the GTP γ S binding buffer (50 mM Hepes, 20 mM NaOH, 100 mM NaCl, 1 mM EDTA, 5 mM MgCl_2 , pH 7.4, 0.1% BSA). The EC₅₀ and E_{max} of the compounds of the invention are evaluated from 10-point dose-response curves done in 300 μl with the appropriate amount of membrane protein and 100000-130000 dpm of GTP γ ³⁵S per well (0.11 – 0.14 nM). The basal and maximal stimulated binding is determined in absence and presence of 1 μM (hCB₂) or 10 μM (hCB₁) Win 55,212-2 respectively. The membranes are pre-incubated for 5 minutes with 56.25 μM (hCB₂) or 112.5 μM (hCB₁) GDP prior to distribution in plates (15 μM (hCB₂) or 30 μM (hCB₁) GDP final). The plates are vortexed and incubated for 60 minutes at room temperature, filtered on Unifilters GF/B (presoaked in water) with the Tomtec or Packard harvester using 3 ml of wash buffer (50 mM Tris, 5 mM MgCl_2 , 50 mM NaCl, pH 7.0). The filters are dried for 1 hour at 55 $^{\circ}\text{C}$. The radioactivity (cpm) is counted in a TopCount (Packard) after adding 65 μl /well of MS-20 scintillation liquid. Antagonist reversal studies are done in the same way except that (a) an agonist dose-response curve is done in the presence of a constant concentration of antagonist, or (b) an antagonist dose-response curve is done in the presence of a constant concentration of agonist.

Based on the above assays, the dissociation constant (K_i) for a particular compound of the invention towards a particular receptor is determined using the following equation:

$$K_i = \text{IC}_{50} / (1 + [\text{rad}] / K_d),$$

Wherein IC₅₀ is the concentration of the compound of the invention at which 50% displacement has been observed;

[rad] is a standard or reference radioactive ligand concentration at that moment; and

K_d is the dissociation constant of the radioactive ligand towards the particular receptor.

- 24 -

Using above-mentioned assays, the K_i towards human CB_1 receptors for most compounds of the invention is measured to be in the range of 36-5700 nM. The K_i towards human CB_2 receptors for most compounds of the invention is measured to be in the range of about 1.6-36 nM.


5 Using the above described assays, the IC_{50} towards CB_1 receptor for most of the compounds of the present invention is generally in the range of 14.1 nM – 3920.3 nM.

EXAMPLES

The invention will further be described in more detail by the following Examples which describe methods whereby compounds of the present invention may be prepared, purified, analyzed and biologically tested, and which are not to be construed as limiting the invention.


Example 1

***N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylthiophene-2-carboxamide**



15

Step A. *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylthiophene-2-carboxamide



2-*tert*-Butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine (30 mg, 0.100 mmol) (for preparation, see the following steps B to F) and a catalytic amount of DMAP were dissolved in 3 mL of dichloromethane. 2-Thiophenecarbonyl chloride (0.013 mL, 0.120 mmol) was added and the solution was stirred at RT overnight. The solution was concentrated and the product was purified by reversed-phase HPLC using 20-80% CH_3CN/H_2O and then lyophilized to afford the desired title compound as the corresponding TFA salt. Yield: 35 mg (67%); 1H NMR (400 MHz, METHANOL- D_4) δ 1.22 (m, 5 H), 1.61

25

- 25 -


(m, 1 H), 1.63 (m, $J=1.17$ Hz, 1 H), 1.65 (s, 9 H), 1.68 (m, 1 H), 1.75 (m, 2 H), 2.10 (m, 1 H), 3.48 (s, 3 H), 4.46 (d, $J=7.62$ Hz, 2 H), 6.79 (dd, $J=4.98, 3.81$ Hz, 1 H), 6.85 (dd, $J=3.91, 1.17$ Hz, 1 H), 7.45 (dd, $J=5.08, 1.17$ Hz, 1 H), 7.53 (dd, $J=8.88, 2.05$ Hz, 1 H), 7.68 (d, $J=1.95$ Hz, 1 H), 7.95 (d, $J=8.79$ Hz, 1 H); MS (ESI) ($M+H$)⁺: 410.2.

5 **Step B. Methyl (4-fluoro-3-nitrophenyl)carbamate**




Methyl chloroformate (13.2 mL, 170.2 mmol) was added dropwise to a cold (0°C) dichloromethane (200 mL) solution of 4-fluoro-3-nitro aniline (24.15 g, 154.7 mmol) and DIPEA (35 mL, 201 mmol). The reaction mixture was stirred at rt overnight. The solution
 10 was then diluted with 200 mL of dichloromethane and washed with 2M HCl, brine and dried over anhydrous MgSO₄. The solvent was concentrated and the product directly used in the next step without further purification. Yield: 35.5 g (99%); ¹H NMR (400 MHz, CHLOROFORM-D) δ 3.81 (s, 3 H), 7.02 (s, 1 H), 7.23 (m, 1 H), 7.72 (d, $J=8.59$ Hz, 1 H), 8.17 (dd, $J=6.35, 2.64$ Hz, 1 H).

15 **Step C. Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate**




Methyl (4-fluoro-3-nitrophenyl)carbamate (1.00 g, 4.67 mmol) and cyclohexylmethyl amine (0.730 mL, 5.60 mmol) were stirred in EtOH (20 mL) containing TEA (1.0 mL, 7.00 mmol) at 75°C for 24h. The solvent was concentrated. The residue was dissolved in EtOAc and
 20 washed with 5% KHSO₄ aqueous solution, saturated NaHCO₃ aqueous solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography using 4:1/hexanes:EtOAc on silica gel. Yield: 1.05 g (73%); ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.04 (m, 2H), 1.25 (m, 3H), 1.69 (m, 2H), 1.77 (m, 2H), 1.83 (m, 1H), 1.86 (m, 1H), 3.14 (m, 2H), 3.78 (s, 3H), 6.46 (m, 1H), 6.84 (d, $J=9.37$, 1H), 7.63 (m, 1H),
 25 8.05 (d, $J=2.54$ Hz, 1H), 8.09 (m, 1H).

- 26 -

Step D. Methyl {3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate

Methyl {4-[(cyclohexylmethyl)amino]-3-nitrophenyl}carbamate (1.05 g, 3.42 mmol) was dissolved in 30 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H₂ atmosphere (40 psi) at RT overnight. The solution was filtered through Celite and the solvent was evaporated. The product was directly used in the next step without further purification. Yield: 950 mg (99%). MS (ESI) (M+H)⁺: 277.9.


Step E. Methyl [2-*tert*-butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]carbamate

Methyl {3-amino-4-[(cyclohexylmethyl)amino]phenyl}carbamate (950 mg, 3.43 mmol) and DMAP (100 mg, 0.858 mmol) were dissolved in 25 mL of dichloromethane. Trimethylacetyl chloride (0.460 mL, 3.77 mmol) was added dropwise and the solution stirred at RT for 1h.


The solvent was concentrated. The residue was divided in two and each of them dissolved in 3 mL of glacial AcOH in a sealed tube. The solutions were heated at 150°C using a Personal Chemistry Smith Synthesizer microwave instrument for three intervals of 30min (3 X 30min). The two tubes were combined and the solvent was evaporated. The residue was dissolved in EtOAc and washed with saturated NaHCO₃ aqueous solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography using

3:1/dichloromethane:diethyl ether on silica gel. Yield: 656 mg (56%); ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.09 (m, 2H), 1.16 (m, 4H), 1.54 (s, 9H), 1.65 (m, 1H), 1.62 (m, 1H), 1.70 (m, J = 1.56Hz, 2H), 1.73 (dd, J = 5.96, 3.22Hz, 2H), 2.02 (m, 1H), 3.78 (s, 3H), 4.10 (d, J = 7.42Hz, 2H), 6.64 (m, 1H), 7.25 (d, J = 8.79Hz, 1H), 7.39 (m, 1H), 7.59 (d, J = 1.76Hz, 1H).

- 27 -

Step F. 2-*tert*-Butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine


Methyl [2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]carbamate (650 mg, 1.89 mmol) was dissolved in 20 mL of THF at 0°C under nitrogen. 1M HCl/ether (2.65 mL, 2.65 mmol) was added dropwise and the solution stirred at 0°C for 15min. LiAlH₄ (360 mg, 9.45 mmol) was then slowly added and the solution stirred at RT overnight. The reaction mixture was quenched at 0°C by addition of MeOH (5 mL) followed by water (10 mL). The solution was diluted with EtOAc and washed with saturated NaHCO₃ aqueous solution, brine and dried over anhydrous MgSO₄. The solvent was evaporated and the product was used directly in the next step without further purification. Yield: 544 mg (96%). ¹H NMR (400 MHz, CHLOROFORM-D) δ 1.08 (m, 2 H), 1.17 (m, 3 H), 1.53 (s, 9 H), 1.64 (s, 2 H), 1.67 (s, 2 H), 1.72 (m, 2 H), 2.02 (m, 1 H), 2.86 (s, 3 H), 4.06 (d, *J*=7.42 Hz, 2 H), 6.60 (dd, *J*=8.69, 2.25 Hz, 1 H), 6.99 (d, *J*=2.15 Hz, 1 H), 7.12 (d, *J*=8.59 Hz, 1 H).

Example 2***N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,2,2-trimethylpropanamide**


Following the same procedure used in Example 1, Step A, using 2-*tert*-butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine (40 mg, 0.134 mmol) and trimethylacetyl chloride (0.021 mL, 0.174 mmol) in 3mL of dichloromethane. The product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O on a C-18 column and then lyophilized to afford the desired title compound as the corresponding TFA salt. Yield: 60 mg (90%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.07 (s, 9 H), 1.23 (m, 5 H), 1.63 (m, 2 H), 1.66 (s, 10 H), 1.76 (m, 2 H), 2.11 (m, 1 H), 3.28 (s, 3 H), 4.47 (d, *J*=7.62 Hz, 2 H), 7.51 (dd,

- 28 -

J=8.79, 1.95 Hz, 1 H), 7.65 (d, J=1.37 Hz, 1 H), 7.96 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺: 384.3; Anal. Calcd for C₂₄H₃₇N₃O + 1.7 TFA + 0.6 H₂O: C, 55.95; H, 6.84; N, 7.14. Found: C, 55.92; H, 6.81; N, 7.07.

Example 3**5 N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,2-dimethylpropanamide**

Following the same procedure used in Example 1, Step A, using 2-*tert*-butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine (40 mg, 0.134 mmol) and isobutyryl chloride (0.018 mL, 0.174 mmol) in 3mL of dichloromethane. The product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O on a C-18 column and then lyophilized to afford the desired title compound as the corresponding TFA salt. Yield: 58 mg (90%); ¹H NMR (400 MHz, METHANOL-D₄) δ 0.99 (s, 6 H), 1.24 (m, 5 H), 1.65 (m, 2 H), 1.66 (s, 10 H), 1.76 (s, 2 H), 2.11 (m, 1 H), 2.46 (m, 1 H), 3.27 (s, 3 H), 4.47 (d, J=7.62 Hz, 2 H), 7.52 (d, J=8.59 Hz, 1 H), 7.67 (s, 1 H), 7.99 (d, J=8.79 Hz, 1 H); MS (ESI) (M+H)⁺: 370.2; Anal. Calcd for C₂₃H₃₅N₃O + 1.7 TFA + 0.3 H₂O: C, 55.75; H, 6.61; N, 7.39. Found: C, 55.77; H, 6.52; N, 7.45.

Example 4**N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,3-dimethylbutanamide**


Following the same procedure used in Example 1, Step A, using 2-*tert*-butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine (30 mg, 0.100 mmol) and isovaleryl chloride (0.016 mL, 0.130 mmol) in 3mL of dichloromethane. The product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O on a C-18 column and then lyophilized to afford the desired title compound as the corresponding TFA salt. Yield: 40 mg (80%); ¹H NMR (400 MHz, METHANOL-D₄) δ 0.79 (brs, 6H), 1.22 (brs, 6H), 1.63 (s, 13H), 1.75 (brs,

- 29 -

1H), 1.97 (m, 1H), 2.03 (m, 1H), 2.10 (m, 1H), 3.27 (s, 3H), 4.41 (d, J = 7.42Hz, 2H), 7.40 (dd, J = 1.66, 8.88Hz, 1H), 7.58 (s, 1H), 7.88 (d, J = 8.79Hz, 1H); MS (ESI) (M+H)⁺: 384.3; Anal. Calcd for C₂₄H₃₇N₃O + 1.0 TFA + 0.3 H₂O: C, 62.08; H, 7.73; N, 8.35. Found: C, 62.18; H, 7.57; N, 8.36.

5 Example 5


N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N'*-isopropyl-*N*-methylurea



Following the same procedure used in Example 1, Step A, using 2-*tert*-butyl-1-(cyclohexylmethyl)-*N*-methyl-1*H*-benzimidazol-5-amine (40 mg, 0.134 mmol) and isopropyl isocyanate (0.015 mL, 0.161 mmol) in 5mL of dichloromethane. The product was purified by reversed-phase HPLC using 20-80% CH₃CN/H₂O on a C-18 column and then lyophilized to afford the desired title compound as the corresponding TFA salt. Yield: 54 mg (81%); ¹H NMR (400 MHz, METHANOL-D₄) δ 1.10 (d, J=6.44 Hz, 6 H), 1.22 (m, 5 H), 1.63 (m, 2 H), 1.66 (s, 9 H), 1.67 (m, 1 H), 1.75 (m, 2 H), 2.11 (m, 1 H), 3.28 (s, 3 H), 3.90 (q, J=6.59 Hz, 1 H), 4.45 (d, J=7.62 Hz, 2 H), 7.47 (dd, J=8.98, 1.95 Hz, 1 H), 7.60 (d, J=1.56 Hz, 1 H), 7.89 (d, J=8.98 Hz, 1 H); MS (ESI) (M+H)⁺: 385.2; Anal. Calcd for C₂₃H₃₆N₄O + 1.5 TFA + 0.4 H₂O: C, 55.49; H, 6.86; N, 9.95. Found: C, 55.42; H, 6.83; N, 9.98.

Example 6

N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]acetamide



20

Step A. *N*-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]acetamide

- 30 -



DMAP (0.65 g, 5.3 mmol) was added to a suspension of *N*-{3-amino-4-[(cyclohexylmethyl)amino]phenyl}acetamide (2.09 g, 8.0 mmol) (for preparation, see the following steps B, C and D) in dichloromethane (40 mL) at -10°C , followed by addition of
 5 2,2-dimethylbutyryl chloride (1.51 g, 11.2 mmol). The resulting mixture was stirred overnight at room temperature. After evaporation of the solvent, 4.14 g of a brown solid was obtained, which was consistent with the desired coupling product. MS (ESI) $(\text{M}+\text{H})^{+} = 360.07$.

308 mg of the above crude product was dissolved in 1,2-dichloroethane (5 mL) in a Teflon-capped test tube. The vessel was irradiated by microwave for 3 h at 170°C . The mixture was
 10 diluted with EtOAc (100 mL), washed with 2N NaOH aqueous solution (10 mL), saturated NaCl aqueous solution (10 mL) and dried over Na_2SO_4 . After filtration and evaporation, the residue was purified by MPLC (EtOAc as eluent on silica gel) to give the desired title compound as a light yellow solid (111.0 mg, 55%). ^1H NMR (400 MHz, CD_3OD): δ 0.84 (t, $J=7.52$ Hz, 3 H), 1.25 (m, 5 H), 1.63 (m, 2 H), 1.66 (s, 6 H), 1.70 (m, 1 H), 1.77 (m, 2 H),
 15 2.01 (q, $J=7.42$ Hz, 2 H), 2.10 (m, 1 H), 2.18 (s, 3 H), 4.44 (d, $J=7.81$ Hz, 2 H), 7.50 (dd, $J=8.98, 1.95$ Hz, 1 H), 7.84 (d, $J=9.18$ Hz, 1 H), 8.44 (d, $J=1.76$ Hz, 1 H). MS (ESI) $(\text{M}+\text{H})^{+}$: 342.05. Anal. Calcd for $\text{C}_{21}\text{H}_{31}\text{N}_3\text{O}+1.10 \text{ TFA}+0.40 \text{ H}_2\text{O}$ (474.13): C, 58.77; H, 6.99; N, 8.66. Found: C, 58.86; H, 6.90; N, 8.91.


20 **Step B. *N*-(4-fluoro-3-nitrophenyl)acetamide**



4-Fluoro-3-nitro-aniline (45.0 g, 288.2 mmol) was added portionwise to acetic anhydride (150 mL) at room temperature. The reaction mixture was stirred at room temperature for 2 h. The white solid was collected and dried *in vacuo* to give the desired title compound (42.0 g, 70%).
 25 ^1H NMR (400 MHz, CDCl_3): δ 2.23 (s, 3 H), 7.26 (m, 1 H), 7.50 (s broad, 1 H), 7.87 (m, 1 H), 8.23 (dd, $J=6.44, 2.73$ Hz, 1 H).


Step C. *N*-{4-[(cyclohexylmethyl)amino]-3-nitrophenyl}acetamide

- 31 -



Cyclohexylmethylamine (2.86 mL, 2.49 g, 22.0 mmol) was added to a mixture of *N*-(4-fluoro-3-nitrophenyl)acetamide (3.96 g, 20.0 mmol) and sodium carbonate (4.66 g, 44 mmol) in EtOH (50 mL) at room temperature. The reaction mixture was heated for 48 h at 60 °C, and
 5 diluted with H₂O (800 mL). The orange solid was precipitated out and collected to give the desired title product (6.60 g, 100%). MS (ESI) (M+H)⁺: 292.32.


Step D. *N*-{3-amino-4-[(cyclohexylmethyl)amino]phenyl}acetamide



The above crude product (*N*-{4-[(cyclohexylmethyl)amino]-3-nitrophenyl}acetamide) was
 10 hydrogenated in ethyl acetate (300 mL) catalyzed by 10% Pd/C (0.5 g) at 20-30 psi H₂ in Parr shaker for 4.5 h at room temperature. After filtration through celite and concentration, 5.08 g (97%) of a purple solid was obtained. which was used in the next step without further purification. ¹H NMR (400 MHz, CDCl₃): δ 1.00 (m, 2 H), 1.24 (m, 3 H), 1.59 (m, 2 H), 1.72 (m, 2 H), 1.84 (m, 2 H), 2.13 (s, 3 H), 2.91 (d, *J*=6.64 Hz, 2 H), 3.37 (s broad, 3 H), 6.56 (d,
 15 *J*=8.40 Hz, 1 H), 6.69 (dd, *J*=8.30, 2.25 Hz, 1 H), 6.98 (s, 1 H), 7.12 (d, *J*=2.34 Hz, 1 H). MS (ESI) (M+H)⁺: 262.31.


Example 7

***N*-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]-*N'*-isopropylurea**




- 32 -

Step A. *N*-[1-(cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]-*N'*-isopropylurea



- 5 A mixture of 1-(cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-amine hydrochloride (48.5 mg, 0.127 mmol), diisopropylethylamine (148 mg, 200 μ L, 1.15 mmol) and isopropylisocyanate (0.5 mL) in 1,2-dichloroethane (5 mL) was heated for 2 h at 60 $^{\circ}$ C. Upon evaporation of the solvent, the residue was treated with 2N NaOH aqueous solution (5 mL), extracted with EtOAc (3x20 mL). The combined organic phases were washed with
- 10 saturated NaCl aqueous solution (10 mL) and dried over Na_2SO_4 . After filtration and evaporation, the residue was purified by MPLC (EtOAc as eluent on silica gel) to give the desired title compound as a syrup (34.8 mg, 71%). ^1H NMR (400 MHz, CD_3OD): δ 0.84 (t, $J=7.52$ Hz, 3 H), 1.20 (d, $J=6.44$ Hz, 6 H), 1.25 (m, 5 H), 1.63 (m, 2 H), 1.66 (s, 6 H), 1.70 (m, 1 H), 1.78 (m, 2 H), 2.00 (q, $J=7.42$ Hz, 2 H), 2.10 (m, 1 H), 3.91 (m, 1 H), 4.42 (d,
- 15 $J=7.62$ Hz, 2 H), 7.28 (m, 1 H), 7.76 (d, $J=9.18$ Hz, 1 H), 8.18 (d, $J=1.56$ Hz, 1 H). MS (ESI) $(\text{M}+\text{H})^+$: 385.2. Anal. Calcd for $\text{C}_{23}\text{H}_{36}\text{N}_4\text{O}+1.20$ TFA $+0.80$ H_2O (535.81): C, 56.94; H, 7.30; N, 10.46. Found: C, 56.90; H, 7.27; N, 10.27.

Step B. 1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-amine




- 20 *N*-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]acetamide (105.4 mg, 0.309 mmol) was dissolved in ethanol (3 mL) and 2N HCl aqueous solution (2 mL) in a Teflon-capped test tube. The vessel was irradiated by microwave for 45 min. at 120 $^{\circ}$ C. After evaporation and drying *in vacuo*, 117.8 mg (100%) of the title compound was obtained as a
- 25 grey white solid. ^1H NMR (400 MHz, CD_3CD): δ 0.87 (t, $J=7.52$ Hz, 3 H), 1.27 (m, 5 H), 1.66 (m, 3 H), 1.71 (s, 6 H), 1.78 (m, 2 H), 2.05 (q, $J=7.42$ Hz, 2 H), 2.13 (m, 1 H), 4.53 (d,

- 33 -

$J=7.62$ Hz, 2 H), 7.66 (dd, $J=8.79$, 1.56 Hz, 1 H), 7.97 (d, $J=1.76$ Hz, 1 H), 8.17 (d, $J=8.79$ Hz, 1 H). MS (ESI) $(M+H)^+$: 300.05.

Example 8


***N*-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]-2,2-dimethylbutanamide**



2,2-Dimethylbutyryl chloride (24.6 mg, 0.18 mmol) was added to a mixture of 1-(cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-amine hydrochloride (65.0 mg, 0.15 mmol) (for preparation see in Example 7, step B) and DMAP (73.3 mg, 0.60 mmol) in acetonitrile (5 mL) at 0 °C. The mixture was stirred for 6 h at room temperature, diluted with EtOAc (50 mL), washed with saturated NaHCO₃ aqueous solution (10 mL), saturated NaCl aqueous solution (10 mL) and dried over Na₂SO₄. After filtration and evaporation, the residue was purified by MPLC (EtOAc as eluent on silica gel) to give the desired title compound as a syrup (51.6 mg, 87%). ¹H NMR (400 MHz, CD₃OD): δ 0.84 (t, $J=7.52$ Hz, 3 H), 0.91 (t, $J=7.52$ Hz, 3 H), 1.25 (m, 5 H), 1.28 (s, 6 H), 1.64 (m, 3 H), 1.67 (s, 6 H), 1.72 (q, $J=7.49$ Hz, 2 H), 1.78 (m, 2 H), 2.02 (q, $J=7.49$ Hz, 2 H), 2.13 (m, 1 H), 4.45 (d, $J=7.62$ Hz, 2 H), 7.64 (dd, $J=8.98$, 1.76 Hz, 1 H), 7.85 (d, $J=9.18$ Hz, 1 H), 8.34 (s, 1 H). MS (ESI) $(M+H)^+$: 398.3. Anal. Calcd for C₂₅H₃₉N₃O+1.50 TFA+0.70 H₂O (581.25): C, 57.86; H, 7.27; N, 7.23. Found: C, 57.90; H, 7.19; N, 7.34.

Example 9

***N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]acetamide**



Following the same procedure of Example 6, a mixture of *N*-{3-amino-4-

[(cyclohexylmethyl)amino]phenyl}acetamide (1.57 g, 6.0 mmol) (for preparation see in


- 34 -

Example 6, step D) and DMAP (0.15 g, 1.2 mmol) in dichloromethane (70 mL) was treated with trimethylacetyl chloride (0.83 g, 6.6 mmol) at -10°C . After evaporation of the solvent, the residue was dissolved in 1,2-dichloroethane (40 mL) and then divided into eight Teflon-capped test tubes. The vessels were irradiated by microwave for 2h at 170°C . After


5 purification by MPLC (EtOAc as eluent on silica gel), the desired title compound was obtained as a white solid (1.42 g, 72%). ^1H NMR (400 MHz, CD_3OD): δ 1.24 (m, 5 H), 1.64 (m, 2 H), 1.67 (s, 9 H), 1.70 (m, 1 H), 1.77 (m, 2 H), 2.12 (m, 1 H), 2.18 (s, 3 H), 4.45 (d, $J=7.62$ Hz, 2 H), 7.50 (m, 1 H), 7.84 (d, $J=8.98$ Hz, 1 H), 8.43 (d, $J=1.95$ Hz, 1 H). MS (ESI) $(\text{M}+\text{H})^+$: 328.3. Anal. Calcd for $\text{C}_{20}\text{H}_{29}\text{N}_3\text{O}+1.20$ TFA +0.30 H_2O (469.71): C, 57.28; H, 6.61; N, 8.95. Found: C, 57.34; H, 6.67; N, 8.85.

Example 10


N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylacetamide



Sodium hydride (201.5mg, 5.04 mmol) was added to a solution of *N*-[2-*tert*-butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]acetamide (549.8 mg, 1.68 mmol) (for preparation see in Example 9) in THF (50 mL) at 0°C . Stirring for 30 min., iodomethane was added. The resulting mixture was stirred overnight at room temperature and quenched with saturated NaHCO_3 aqueous solution (5 mL) and water (10 mL). Two phases were separated. The aqueous was extracted with EtOAc (3x20 mL). The combined organic phases were washed with saturated NaHCO_3 aqueous solution (20 mL), saturated NaCl aqueous solution (20 mL) and dried over Na_2SO_4 . After evaporation of the solvent, the residue was purified by MPLC (EtOAc as eluent on silica gel) to give the desired title compound as a white solid (580.5 mg, 100%). ^1H NMR (400 MHz, CD_3OD): δ 1.26 (m, 5 H), 1.67 (m, 2 H), 1.69 (s, 9 H), 1.71 (m, 1 H), 1.78 (m, 2 H), 1.87 (s, 3 H), 2.14 (m, 1 H), 3.30 (s, 3 H), 4.49 (d, $J=7.62$ Hz, 2 H), 7.55 (d, $J=8.40$ Hz, 1 H), 7.71 (s, 1 H), 8.00 (d, $J=8.40$ Hz, 1 H). MS (ESI) $(\text{M}+\text{H})^+$: 342.3. Anal. Calcd for $\text{C}_{21}\text{H}_{31}\text{N}_3\text{O}+1.30$ TFA+0.80 H_2O (504.14): C, 56.23; H, 6.78; N, 8.33. Found: C, 56.21; H, 6.77; N, 8.17.

Example 11**N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-2,2-dimethylpropanamide**

5

Step A: N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1H-benzimidazol-5-yl]-2,2-dimethylpropanamide


10

N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyl}-2,2-dimethylpropanamide (for preparation, see following Steps B to D) (174 mg, 0.573 mmol) and DMAP (18 mg, 0.143 mmol) were dissolved in 5 mL of DCM. Trimethylacetyl chloride (0.077 mL, 0.630 mmol) was added dropwise and the solution was stirred at RT for 1h. The solvent was evaporated.

15 The residue was dissolved in 3 mL of glacial acetic acid in a sealed tube and the solution was heated at 150°C in a Smithsynthesizer (Personal Chemistry) microwave instrument for 1h. The solvent was evaporated *in vacuo*. The residue was dissolved in EtOAc and washed with saturated NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The product was

20 lyophilized affording the desired title compound as the corresponding TFA salt. Yield: 170 mg (61%). ¹H NMR (400 MHz, METHANOL-D₄): δ 1.21 (m, 5 H), 1.29 (s, 9 H), 1.61 (m, 2 H), 1.64 (s, 9 H), 1.66 (m, 1 H), 1.75 (m, 2 H), 2.09 (m, 1 H), 4.42 (d, J=7.62 Hz, 2 H), 7.62 (dd, J=9.18, 1.95 Hz, 1 H), 7.81 (d, J=9.18 Hz, 1 H), 8.31 (d, J=1.56 Hz, 1 H); MS (ESI) (M+H)⁺ 370.2; Anal. Calcd for C₂₃H₃₅N₃O + 1.6 TFA + 0.2 H₂O: C, 56.64; H, 6.71; N, 7.56.


25 Found: C, 56.67; H, 6.74; N, 7.53.

Step B: N-(4-Fluoro-3-nitrophenyl)-2,2-dimethylpropanamide

5

4-Fluoro-3-nitroaniline (500 mg, 3.20 mmol) and DMAP (586 mg, 4.80 mmol) were dissolved in 25 mL of DCM. Trimethylacetyl chloride (0.587 mL, 4.80 mmol) was added dropwise and the solution was stirred at rt for 3h. The solution was washed with 5% KHSO₄ solution, saturated NaHCO₃ solution, brine and dried over anhydrous MgSO₄. The crude product was purified by flash chromatography using 35% EtOAc in hexanes as eluent on silica gel to produce the desired title compound. Yield: 713 mg (93%). ¹H NMR (400 MHz, CHLOROFORM-D): δ 1.34 (s, 9 H), 7.25 (dd, J=10.25, 9.08 Hz, 1 H), 7.50 (br.s, 1 H), 7.88 (ddd, J=9.08, 3.71, 2.83 Hz, 1 H), 8.26 (dd, J=6.44, 2.73 Hz, 1 H).

10

Step C: N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}-2,2-dimethylpropanamide


15

N-(4-Fluoro-3-nitrophenyl)-2,2-dimethylpropanamide (158 mg, 0.658 mmol) and cyclohexylmethylamine (0.100 mL, 0.790 mmol) were stirred in 3 mL of EtOH containing triethylamine (0.140 mL, 0.987 mmol) at 75°C for 24h. The solvent was evaporated. The residue was dissolved in EtOAc and washed with 5% KHSO₄ solution, saturated NaHCO₃ solution, brine and dried over anhydrous MgSO₄. Yield: 217 mg (99%). ¹H NMR (400 MHz, CHLOROFORM-D): δ 0.98-1.09 (m, 2 H), 1.17-1.28 (m, 3 H), 1.31 (s, 9 H), 1.65-1.73 (m, 2 H), 1.74-1.80 (m, 2 H), 1.82-1.84 (m, 1 H), 1.85-1.88 (m, 1 H), 3.15 (dd, J=6.64, 5.47 Hz, 2 H), 6.83 (d, J=9.37 Hz, 1 H), 7.23 (br.s, 1 H), 7.82 (dd, J=9.18, 2.54 Hz, 1 H), 8.10 (d, J=2.54 Hz, 1 H), 8.11-8.13 (m, 1 H).

20

25

- 37 -

Step D: N-{3-Amino-4-[(cyclohexylmethyl)amino]phenyl}-2,2-dimethylpropanamide


- 5 N-{4-[(Cyclohexylmethyl)amino]-3-nitrophenyl}-2,2-dimethylpropanamide (215 mg, 0.645 mmol) was dissolved in 20 mL of EtOAc containing a catalytic amount of 10% Pd/C. The solution was shaken in a Parr hydrogenation apparatus under H₂ atmosphere (45 psi) at RT for 24h. The solution was filtered through Celite and the solvent evaporated to give the desired product. Yield: 175 mg (89%); MS (ESI) (M+H)⁺ 304.04.

10

15

What is claimed is:

1. A compound of formula I or a pharmaceutically acceptable salt thereof:



I

wherein

Z is selected from O= and S=;

- R¹ is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R⁵R⁶N-C₁₋₆alkyl, R⁵O-C₁₋₆alkyl, R⁵C(=O)N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂-C₁₋₆alkyl, R⁵CS(=O)₂N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NC(=O)N(-R⁷)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂N(R⁷)-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, R⁵R⁶N-, R⁵O-, R⁵C(=O)N(-R⁶)-, R⁵R⁶NS(=O)₂-, R⁵CS(=O)₂N(-R⁶)-, R⁵R⁶NC(=O)N(-R⁷)-, R⁵R⁶NS(=O)₂N(R⁷)-, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl or C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;
- R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R⁵R⁶N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and -NR⁵R⁶;

- 39 -

wherein R^5 , R^6 and R^7 are independently selected from -H, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and a divalent C_{1-6} group that together with another divalent R^5 , R^6 or R^7 forms a portion of a ring; and

R^3 is selected from R^8 , R^8O- , and R^8R^9N- ;

- 5 each of R^4 , R^8 and R^9 is independently selected from -H, C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{3-6} heterocyclyl, C_{6-10} aryl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{6-10} aryl- C_{1-6} alkyl, and a divalent C_{1-6} group that together with another divalent group selected from R^4 , R^8 and R^9 forms a portion of a ring, wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{3-10} cycloalkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{3-6} heterocyclyl, C_{6-10} aryl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{6-10} aryl- C_{1-6} alkyl, or divalent C_{1-6} group is
- 10 optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino.

2. A compound as claimed in claim 1, wherein

- 15 Z is O=;

R^1 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $R^5R^6N-C_{1-4}$ alkyl, R^5O-C_{1-4} alkyl, $R^5C(=O)N(-R^6)-C_{1-4}$ alkyl, phenyl- C_{1-4} alkyl, phenyl- $C(=O)-C_{1-4}$ alkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- $C(=O)-C_{1-4}$ alkyl, R^5R^6N- , R^5O- , $R^5R^6NS(=O)_2-$, C_{6-10} aryl, C_{6-10} aryl- $C(=O)-$, C_{3-10} cycloalkyl, C_{4-6} cycloalkenyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl- $C(=O)-$; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl- C_{1-4} alkyl, phenyl- $C(=O)-C_{1-4}$ alkyl, C_{3-10} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- $C(=O)-C_{1-4}$ alkyl, C_{6-10} aryl, C_{6-10} aryl- $C(=O)-$, C_{3-10} cycloalkyl, C_{4-6} cycloalkenyl, C_{3-6} heterocyclyl or C_{3-6} heterocyclyl- $C(=O)-$ used in defining R^1 is optionally substituted by one or more groups

- 20 selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;
- wherein R^5 and R^6 are independently selected from -H, C_{1-6} alkyl and C_{2-6} alkenyl;

R^2 is selected from the group consisting of C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl, C_{3-5} heteroaryl, R^5R^6N- , phenyl and C_{3-6} heterocycloalkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl, C_{3-5} heteroaryl, phenyl or C_{3-6} heterocycloalkyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; and

30

- 40 -

R^3 is selected from R^8 , R^8O -, R^8HN - and R^8R^9N -;

R^8 and R^9 are independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocyclyl, phenyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, and phenyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocyclyl, phenyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, or phenyl- C_{1-4} alkyl is optionally substituted

by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; and

R^4 is selected from $-H$, C_{1-6} alkyl and C_{2-6} alkenyl.

3. A compound as claimed claim 1, wherein

Z is $O=$;

R^1 is selected from C_{1-6} alkyl, C_{2-6} alkenyl, R^5R^6N - C_{1-4} alkyl, R^5O - C_{1-4} alkyl, $R^5C(=O)N(-R^6)$ - C_{1-4} alkyl, phenyl- C_{1-4} alkyl, phenyl- $C(=O)$ - C_{1-4} alkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-4} alkyl, phenyl, C_{3-6} cycloalkyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl- $C(=O)$ -; wherein said C_{1-6} alkyl, C_{2-6} alkenyl, R^5R^6N - C_{1-4} alkyl, R^5O - C_{1-4} alkyl, $R^5C(=O)N(-R^6)$ - C_{1-4} alkyl, phenyl- C_{1-4} alkyl, phenyl- $C(=O)$ - C_{1-4} alkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{4-6} cycloalkenyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, C_{3-6} heterocyclyl- $C(=O)$ - C_{1-4} alkyl, phenyl, C_{3-6} cycloalkyl, C_{3-6} heterocyclyl or C_{3-6} heterocyclyl- $C(=O)$ - used in defining R^1 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;

R^2 is selected from the group consisting of C_{1-6} alkyl, C_{3-6} cycloalkyl, R^5R^6N -, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl, C_{3-5} heteroaryl, and phenyl wherein said C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl- C_{1-4} alkyl, C_{3-6} heterocycloalkyl, C_{3-5} heteroaryl, and phenyl used in defining R^2 is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;

R^5 and R^6 are independently selected from $-H$, C_{1-6} alkyl and C_{2-6} alkenyl; and

R^3 is selected from R^8 , R^8O -, R^8HN - and R^8R^9N -;

R^8 and R^9 are independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{3-5} heterocyclyl, phenyl, C_{3-5} heterocyclyl- C_{1-4} alkyl, and phenyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl- C_{1-4} alkyl, C_{3-5} heterocyclyl, phenyl, C_{3-5} heterocyclyl- C_{1-4} alkyl, and phenyl- C_{1-4} alkyl is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy, and $-NR^5R^6$;

- 41 -

heterocyclyl, phenyl, C₃₋₅heterocyclyl-C₁₋₄alkyl, or phenyl-C₁₋₄alkyl is optionally substituted by one or more groups selected from halogen, cyano, methoxy, methyl, and ethyl; and

R⁴ is selected from -H and C₁₋₄alkyl.

5 4. A compound as claimed in claim 1, wherein

Z is O=;

R¹ is selected from cyclohexylmethyl, cyclopentylmethyl, cyclobutylmethyl, cyclopropylmethyl, ethyl, propyl, adamantyl, adamantylmethyl, allyl, isopentyl, benzyl, methoxyethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl, cyclohexyloxy, cyclohexylamino, dimethylaminoethyl, 4-pyridylmethyl, 2-pyridylmethyl, 1-pyrrolylethyl, 1-morpholinoethyl, 4,4-difluorocyclohexylmethyl, cyclohexylmethyl, 2-pyrrolidylmethyl, N-methyl-2-pyrrolidylmethyl, 2-piperidylmethyl, N-methyl-2-piperidylmethyl, 3-thienylmethyl, (2-nitrothiophene-5-yl)-methyl, (1-methyl-1H-imidazole-2-yl)methyl, (5-(acetoxymethyl)-2-furyl)methyl, (2,3-dihydro-1H-isoindole-1-yl)methyl, and 5-(2-methylthiazolyl);

15 R² is selected from t-butyl, n-butyl, 2-methyl-2-butyl, cyclohexyl, cyclohexylmethyl, n-pentyl, isopentyl, trifluoromethyl, 1,1-difluoroethyl, N-piperidyl, dimethylamino, phenyl, pyridyl, tetrahydrofuranyl, tetrahydropyranyl, 2-methoxy-2-propyl and N-morpholinyl;

R³ is selected from methyl, ethyl, isopropyl, n-butyl, t-butyl, iso-butyl, phenyl, pyridyl, imidazolyl, naphthalenyl, isopropylamino and 2-thienyl; and

20 R⁴ is selected from -H, methyl and ethyl.

5. A compound selected from:

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylthiophene-2-carboxamide,

25 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,2,2-trimethylpropanamide,

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,2-dimethylpropanamide,

30 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*,3-dimethylbutanamide,

N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-isopropyl-*N*-methylurea,

N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]acetamide,


- 42 -

N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]-*N'*-isopropylurea,


N-[1-(Cyclohexylmethyl)-2-(1,1-dimethylpropyl)-1*H*-benzimidazol-5-yl]-2,2-dimethylbutanamide,

- 5 *N*-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]acetamide,
 N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-*N*-methylacetamide,
 N-[2-*tert*-Butyl-1-(cyclohexylmethyl)-1*H*-benzimidazol-5-yl]-2,2-dimethylpropanamide, and pharmaceutically acceptable salts thereof.

- 10 6. A compound according to any one of claims 1-5 for use as a medicament.
7. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the therapy of pain.
- 15 8. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of anxiety disorders.
9. The use of a compound according to any one of claims 1-5 in the manufacture of a medicament for the treatment of cancer, multiple sclerosis, Parkinson's disease, Huntington's
- 20 chorea, Alzheimer's disease, gastrointestinal disorders and cardiovascular disorders.
10. A pharmaceutical composition comprising a compound according to any one of claims 1-5 and a pharmaceutically acceptable carrier.
- 25 11. A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to any one of claims 1-5.
12. A method for preparing a compound of formula II,

**II**

comprising the step of reacting a compound of formula III,



III

- 5 with a compound of $R^3C(=O)X$ to form the compound of formula II,
wherein

X is selected from -Cl, -Br, -I, -OH, -OCH₃ and -OCH₂CH₃;

- R^1 is selected from C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, R⁵R⁶N-C₁₋₆alkyl, R⁵O-C₁₋₆alkyl, R⁵C(=O)N(-R⁶)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂-C₁₋₆alkyl, R⁵CS(=O)₂N(-R⁶)-C₁₋₆alkyl,
10 R⁵R⁶NC(=O)N(-R⁷)-C₁₋₆alkyl, R⁵R⁶NS(=O)₂N(R⁷)-C₁₋₆alkyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, R⁵R⁶N-, R⁵O-, R⁵C(=O)N(-R⁶)-, R⁵R⁶NS(=O)₂-, R⁵CS(=O)₂N(-R⁶)-, R⁵R⁶NC(=O)N(-R⁷)-, R⁵R⁶NS(=O)₂N(R⁷)-, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl and C₃₋₆heterocyclyl-C(=O)-; wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₆₋₁₀aryl-C₁₋₆alkyl, C₆₋₁₀aryl-C(=O)-C₁₋₆alkyl, C₃₋₁₀cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C₁₋₆alkyl, C₃₋₆heterocyclyl-C(=O)-C₁₋₆alkyl, C₁₋₁₀hydrocarbylamino, C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl or C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups
20 selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and -NR⁵R⁶;
- R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R⁵R⁶N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl,
25 C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;

- wherein R⁵, R⁶ and R⁷ are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, and a divalent C₁₋₆group that together with another divalent R⁵, R⁶ or R⁷ forms a portion of a ring;
- 30

- 44 -


R^3 is selected from R^8 , R^8O- , R^8NH- , R^8R^9N- ;

R^8 and R^9 are independently selected from C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocyclyl, phenyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, and phenyl- C_{1-4} alkyl, wherein said C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl- C_{1-4} alkyl, C_{3-6} heterocyclyl, phenyl, C_{3-6} heterocyclyl- C_{1-4} alkyl, or phenyl- C_{1-4} alkyl is optionally substituted

by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino; and


R^4 is selected from $-H$, C_{1-6} alkyl and C_{2-6} alkenyl.

13. A method for preparing a compound of formula IV,



IV

comprising the step of reacting a compound of formula V,



V

with a reducing agent selected from AlH_3 , $NaBH_4$, $NaBH(O-iPr)_3$, and $LiAlH_4$, wherein

R^1 is selected from C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, $R^5R^6N-C_{1-6}$ alkyl, R^5O-C_{1-6} alkyl, $R^5C(=O)N(-R^6)-C_{1-6}$ alkyl, $R^5R^6NS(=O)_2-C_{1-6}$ alkyl, $R^5CS(=O)_2N(-R^6)-C_{1-6}$ alkyl, $R^5R^6NC(=O)N(-R^7)-C_{1-6}$ alkyl, $R^5R^6NS(=O)_2N(R^7)-C_{1-6}$ alkyl, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)-C_{1-6}$ alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)-C_{1-6}$ alkyl, C_{1-10} hydrocarbylamino, R^5R^6N- , R^5O- , $R^5C(=O)N(-R^6)-$, $R^5R^6NS(=O)_2-$, $R^5CS(=O)_2N(-R^6)-$, $R^5R^6NC(=O)N(-R^7)-$, $R^5R^6NS(=O)_2N(R^7)-$, C_{6-10} aryl, C_{6-10} aryl- $C(=O)-$, C_{3-10} cycloalkyl, C_{4-8} cycloalkenyl, C_{3-6} heterocyclyl and C_{3-6} heterocyclyl- $C(=O)-$; wherein said C_{1-10} alkyl, C_{2-10} alkenyl, C_{2-10} alkynyl, C_{6-10} aryl- C_{1-6} alkyl, C_{6-10} aryl- $C(=O)-C_{1-6}$ alkyl, C_{3-10} cycloalkyl- C_{1-6} alkyl, C_{4-8} cycloalkenyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- C_{1-6} alkyl, C_{3-6} heterocyclyl- $C(=O)-C_{1-6}$ alkyl, C_{1-10} hydrocarbylamino,

- 45 -

C₆₋₁₀aryl, C₆₋₁₀aryl-C(=O)-, C₃₋₁₀cycloalkyl, C₄₋₈cycloalkenyl, C₃₋₆heterocyclyl or C₃₋₆heterocyclyl-C(=O)- used in defining R¹ is optionally substituted by one or more groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and R⁵R⁶N-;

5 R² is selected from the group consisting of C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, R⁵R⁶N-, C₃₋₅heteroaryl, C₆₋₁₀aryl and C₃₋₆heterocycloalkyl, wherein said C₁₋₁₀alkyl, C₂₋₁₀alkenyl, C₂₋₁₀alkynyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl-C₁₋₆alkyl, C₃₋₆heterocycloalkyl-C₁₋₆alkyl, C₄₋₈cycloalkenyl, C₃₋₅heteroaryl, C₆₋₁₀aryl or C₃₋₆heterocycloalkyl used in defining R² is optionally substituted by one or more
10 groups selected from halogen, cyano, nitro, methoxy, ethoxy, methyl, ethyl, hydroxy and amino;

wherein R⁵, R⁶ and R⁷ are independently selected from -H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, and a divalent C₁₋₆group that together with another divalent R⁵, R⁶ or R⁷ forms a portion of a ring; and

15 R¹⁰ is selected from -H, C₁₋₆alkyl, and C₁₋₆alkenyl.

INTERNATIONAL SEARCH REPORT

ational Application No
PCT/GB2004/002430

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D409/12 C07D235/08 A61K31/4184 A61P29/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BEILSTEIN Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/085866 A (WALPOLE CHRISTOPHER ; CHENG YUN-XING (CA); YANG HUA (CA); TOMASZEWSKI) 31 October 2002 (2002-10-31) the whole document	1-13
X	page 25	12,13
X	EP 0 882 718 A (FUJISAWA PHARMACEUTICAL CO) 9 December 1998 (1998-12-09) the whole document	1-13
	----- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

6 August 2004

Date of mailing of the international search report

23/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Lauro, P

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/002430

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WILLITZER H ET AL: "Synthese und antivirale Wirksamkeit von substituierten 5-Ureido- und 5-Thioureidobenzimidazolderivaten" PHARMAZIE, VEB VERLAG VOLK UND GESUNDHEIT. BERLIN, DD, vol. 33, no. 1, January 1978 (1978-01), pages 30-38, XP002209435 ISSN: 0031-7144 tables 6,7</p>	1-13
X	<p>-----</p> <p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002291482 * BRN 838602 * abstract & KAMEL ET AL.: J. PRAKT. CHEM., vol. 31, 1966, pages 100-105,</p>	1
X	<p>-----</p> <p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002291483 * BRN 926470 * abstract & OSMAN: KOLOR. ERT., vol. 11, 1969, page 118,</p>	1
X	<p>-----</p> <p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002291484 * BRN 311062 * abstract & PINNOW; WISKOTT: CHEM. BER., vol. 32, 1899, page 900,</p>	1
X	<p>-----</p> <p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002291485 * BRN 189489 * abstract & FOSTER: J. CHEM. SOC., 1957, pages 4687-8,</p>	1
X	<p>-----</p> <p>DE 23 00 521 A (MERCK & CO INC) 19 July 1973 (1973-07-19) examples</p> <p>-----</p> <p style="text-align: center;">-/--</p>	1

INTERNATIONAL SEARCH REPORT

tional Application No
PCT/GB2004/002430

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE BEILSTEIN BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002291490 * BRN 326965 * abstract & V. WALTER; KESSLER: J. PRAK.CHEM., vol. 2, no. 74, 1906, page 198,</p> <p>-----</p>	1
X	<p>PATENT ABSTRACTS OF JAPAN vol. 2000, no. 07, 29 September 2000 (2000-09-29) & JP 2000 095767 A (TAKEDA CHEM IND LTD), 4 April 2000 (2000-04-04) abstract</p> <p>-----</p>	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB2004/002430

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 02085866	A	31-10-2002	BR 0208907 A CA 2444381 A1 CZ 20032833 A3 EE 200300524 A EP 1390350 A1 HU 0303825 A2 NO 20034665 A WO 02085866 A1 US 2004116465 A1	20-04-2004 31-10-2002 12-05-2004 16-02-2004 25-02-2004 01-03-2004 10-12-2003 31-10-2002 17-06-2004
EP 0882718	A	09-12-1998	AU 722514 B2 AU 1209597 A BR 9612434 A EA 2357 B1 EP 0882718 A1 IL 124969 A JP 3063162 B2 NZ 324834 A US 6166219 A CA 2241186 A1 CN 1211238 A HU 9900625 A2 WO 9724334 A1 JP 2000159749 A TR 9801249 T2 US 6352985 B1 ZA 9610918 A AU 4400597 A WO 9815530 A1 TW 548272 B ZA 9708998 A	03-08-2000 28-07-1997 28-12-1999 25-04-2002 09-12-1998 12-09-2002 12-07-2000 30-11-2001 26-12-2000 28-06-1997 17-03-1999 28-06-1999 10-07-1997 13-06-2000 21-10-1998 05-03-2002 08-07-1997 05-05-1998 16-04-1998 21-08-2003 20-04-1998
DE 2300521	A	19-07-1973	US 3839347 A AR 203004 A1 AT 321293 B AU 464534 B2 AU 4996472 A BE 793718 A1 BG 21028 A3 DD 103896 A5 DE 2300521 A1 ES 410408 A1 FR 2181654 A1 GB 1398051 A JP 48076871 A LU 66794 A1 NL 7216634 A SU 502606 A3 ZA 7300093 A	01-10-1974 08-08-1975 25-03-1975 28-08-1975 13-06-1974 05-07-1973 20-01-1976 12-02-1974 19-07-1973 16-05-1976 07-12-1973 18-06-1975 16-10-1973 18-07-1973 10-07-1973 05-02-1976 28-08-1974
JP 2000095767	A	04-04-2000	NONE	